TABLE 9.
Norovirus detection using multiplex gastrointestinal pathogen panels
| Study reference | Test | Study location(s) | Case context(s) | Population(s) | Genogroup | Sensitivityc (%) | Specificity (%) | Reference method(s) (reference) |
|---|---|---|---|---|---|---|---|---|
| 216 | xTAG GPPa | International | Sporadic | Pediatric, adult | I | 100.0 | 100.0 | Real-time RT-PCR (218) |
| Multisite | II | 92.5 | 97.6 | |||||
| 219 | xTAG GPP | France | Sporadic | Pediatric, adult | I or II | 0.0 | 93.6 | ImmunoCardSTAT!b |
| 220 | xTAG GPP | United States | Sporadic, outbreak | Pediatric, adult | I | NA | 100.0 | Real-time RT-PCR (202) |
| II | 100.0 | 100.0 | ||||||
| 217 | xTAG GPP | Netherlands | Sporadic | Not specified | I | NA | 100.0 | Real-time RT-PCR (218) |
| II | 94.4 | 100.0 | ||||||
| 222 | TaqMan Array | Tanzania, Bangladesh | Not specified | Pediatric | II | 100.0 | 96.2 | RT-PCR Luminex (223) |
| 224 | BioFire FilmArray GI Panele | United States | Not specified | Not specified | I or II | 96.2d | 99.8 | xTAG GPP,f real-time RT-PCR (202) |
a
Luminex, Austin, TX.
b
Meridian Bioscience Europe, Nice, France.
c
NA, not applicable; genogroup I-positive samples were not detected by the reference method.
d
The composite reference requires at least two positive tests to be considered positive. Sensitivity and specificity were calculated by using both prospective and retrospective samples.
e
bioMérieux, Marcy l'Etoile, France.
f
Utilized stool specimens collected in Carey-Blair medium rather than the manufacturer-recommended raw stool specimens.